Page URL:

Stem cell trial to treat blindness launched in US

20 June 2011
Appeared in BioNews 612

Two clinical trials to test whether embryonic stem cells (ES cells) can treat two incurable eye disorders have been launched in the USA. Twenty-four people will be treated during the trials at the Jules Stein Eye Institute at the University of California, Los Angeles (UCLA). One trial will target dry age-related macular degeneration (AMD), the commonest form of blindness in the developed world and a leading cause of vision loss in people aged 55 and over. The other will treat people with Stargardt's macular dystrophy, an inherited condition that usually develops between the ages of 10 and 20.

Professor Steven Schwartz, who will lead the trials at the Institute, said they 'will mark a significant step towards addressing what is one of the largest unmet medical needs of our time…otherwise untreatable and common forms of legal blindness'. He added: 'The incidence of dry AMD is expected to double over the next 20 years as the population ages'.

Both conditions are caused by the progressive loss of retinal pigment epithelial (RPE) cells, which are found in the eye and support, protect and nourish the light-sensitive cells that provide vision. Patients in the trial will receive eye injections of ES cells programmed to behave like RPE cells. The therapy, developed by Advanced Cell Technology (ACT) in Massachusetts during the past decade, has reportedly produced promising results in rats and mice.

Four different doses of cells will be trialled for each disorder – each on a different group of three people. The programme's initial goal is testing the therapy's safety and tolerability and assessing whether the disorders' progression can be slowed. If successful, future trials will investigate halting or reversing the effects of these disorders.

Professor Schwartz explained: 'This trial will begin the process of understanding whether stem cell-derived RPE cells have the potential to be a safe and effective treatment for these debilitating diseases'.

These trials form the second US programme to investigate the use of human ES cells in medical treatments. The first, run by California-based company Geron, began last year and aims to use ES cells to treat paralysis. 'Initiating these two clinical trials represents an important milestone for ES cell research', said Dr Robert Lanza, chief scientific officer at ACT. 'We hope that these cells will, in the future, provide treatment for not only these two untreatable diseases… but for patients suffering from a range of other [eye disorders]'.

First patients have stem cells injected into their eyes to test 'cure' for blindness
Daily Mail |  17 June 2011
Groundbreaking eye disease treatment trials to begin
Guardian |  16 June 2011
6 February 2012 - by Ruth Retassie 
US company StemCells Inc have received Food and Drug Administration (FDA) authorisation to carry out clinical trials of their treatment for one of the leading causes of blindness in over 55-year-olds...
31 January 2012 - by Rosemary Paxman 
A clinical trial testing the safety of using human embryonic stem cell (hESC) in the treatment of progressive eye conditions has been carried out by researchers in the USA...
31 January 2012 - by Dr Dusko Ilic and Dr Emma Stephenson 
Last week, Advanced Cell Technology (ACT) of Massachusetts, USA, made two important announcements regarding human embryonic stem (hES) cell-based therapies for the potential treatment of Stargardt's dystrophy and age-related macular degeneration, two devastating degenerative disease leading to blindness....
21 November 2011 - by Rosemary Paxman 
A US drug company is abandoning its research into a novel paralysis treatment using embryonic stem cells, due to current economic conditions....
31 October 2011 - by Victoria Kay 
A British man has become the first person to receive an advanced gene therapy treatment in a bid to save his sight. Jonathan Wyatt, aged 63, is the first of 12 patients to have the experimental procedure to try and halt the progression of his genetic eye disorder, choroideraemia. While he still has some sight, if left untreated, he would eventually become blind...
11 April 2011 - by Dr Rachael Panizzo 
Embryonic stem cells have been used to generate a basic retina, the part of the eye that detects light and is needed for vision. The retinal tissue could be used to treat some forms of blindness, such as retinitis pigmentosa and age-related macular degeneration, and to investigate and screen potential new drugs for a range of eye diseases....
28 March 2011 - by Dr Sophie Pryor 
US scientists have taken an important step towards using stem cells to treat age-related macular degeneration (AMD), the leading cause of blindness in the UK. The study demonstrates, for the first time, the ability to direct human iPS (induced pluripotent stem) cells to become...
21 March 2011 - by Dr Lux Fatimathas 
UK scientists have shown stem cells can be used to successfully stop glaucoma, an eye disorder, in rats. Stem cells were isolated from bone marrow and successfully grafted onto damaged nerves in the eye...
27 September 2010 - by Dr Rachael Panizzo 
Researchers have successfully transplanted retinal cone cells into blind mice, making progress towards a stem cell treatment for a form of blindness that causes degeneration of the eye's retina...
8 March 2010 - by Harriet Vickers 
A US company has been granted beneficial 'orphan drug' status by the American Food and Drug Administration (FDA) for an embryonic stem cell therapy it's developing to treat a rare form of blindness...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.